Shanghai Biomabs Pharmaceutical Co., Ltd.
5 clinical trials · Sponsor
◉ Watch Shanghai Biomabs Pharmaceutical Co., Ltd.
| Record | Firm | Date |
|---|---|---|
| Phase I Study to Compare CMAB818 Injection and Lucentis® in Patients With Wet AMD (NCT04884399) | Shanghai Biomabs Pharmaceutical Co., Ltd. | 2021-06-03 |
| Clinical Efficacy and Safety Comparative Study Between CMAB807 Injection and Prolia® . (NCT04591275) | Shanghai Biomabs Pharmaceutical Co., Ltd. | 2021-03-31 |
| Phase 1 Study to Compare CMAB807 Injection to Prolia® in Healthy Volunteers (NCT03925051) | Shanghai Biomabs Pharmaceutical Co., Ltd. | 2019-07-01 |
| Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. (NCT03468790) | Shanghai Biomabs Pharmaceutical Co., Ltd. | 2018-05-09 |
| CMAB008 With MTX Therapy in Adult Patients With Moderately to Severely Active Rheumatoid Arthritis (NCT03478111) | Shanghai Biomabs Pharmaceutical Co., Ltd. | 2018-03-30 |
Track Shanghai Biomabs Pharmaceutical Co., Ltd. automatically
Every clearance here is in the API, with alerts when new ones post.